E3 ubiquitin ligase HECW2: a promising target for tumour therapy.

IF 5.3 2区医学 Q1 ONCOLOGY

Cancer Cell International Pub Date : 2024-11-11 DOI:10.1186/s12935-024-03563-3

Hui Shen, Qianrui Kou, Linxin Shao, Jing Zhang, Fang Li

引用次数: 0

Abstract

Ubiquitination is a prevalent post-translational modification that plays a crucial role in a wide range of pathophysiological processes, including cell proliferation, apoptosis, autophagy, immune response, and DNA damage repair. Among the enzymes involved in ubiquitination, E3 ubiquitin ligases are particularly significant, serving as key regulators of numerous diseases, including tumours. This review focuses on HECW2 (HECT, C2, and WW domain-containing E3 ubiquitin protein ligase 2, also known as NEDL2), providing a comprehensive overview of its interactors and its pathological roles in tumorous cancer and other diseases. The insights gained from this review may contribute to the development of novel treatment strategies for various diseases, particularly tumours.

查看原文本刊更多论文

E3 泛素连接酶 HECW2：有望用于肿瘤治疗的靶点。

泛素化是一种普遍的翻译后修饰，在细胞增殖、凋亡、自噬、免疫反应和 DNA 损伤修复等多种病理生理过程中发挥着至关重要的作用。在参与泛素化的酶中，E3 泛素连接酶尤为重要，是包括肿瘤在内的多种疾病的关键调节因子。本综述以 HECW2（含 HECT、C2 和 WW 结构域的 E3 泛素蛋白连接酶 2，又称 NEDL2）为重点，全面概述了它的相互作用者及其在肿瘤癌症和其他疾病中的病理作用。从这篇综述中获得的见解可能有助于开发治疗各种疾病（尤其是肿瘤）的新策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell International ONCOLOGY-

CiteScore

10.90

自引率

1.70%

发文量

360

审稿时长

1 months

期刊介绍： Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques. The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors. Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.